Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jeffrey Chase

Sports Medicine St Thomas, VI Medical Doctor

NPI 1134211576 CMS profile 566124

9149 Estate Thomas, Paragon Medical Building Ste 104, St Thomas, VI 00802

Open in the dashboard

General payments

$1,538

11 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jeffrey Chase of St Thomas, VI is reported in the CMS Open Payments database as having received $1,538 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 23rd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $157 2
2023 General $188 1
2021 General $60 1
2020 General $116 1
2019 General $1,017 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Chase
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Jeffrey Chase were reported at $0. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Jeffrey Chase Sports Medicine median Middle half National median
2019 $1,017 $1,176 $199–$4,249 $163
2020 $116 $708 $96–$2,890 $114
2021 $60 $1,213 $152–$3,994 $132
2022 $0 $1,230 $159–$3,998 $149
2023 $188 $584 $146–$2,836 $160
2024 $157 $628 $163–$3,168 $164
2025 $0 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Exactech, Inc. $633 4 payments
  2. Linvatec Corporation $560 4 payments
  3. Miach Orthopaedics, Inc. $188 1 payment
  4. US Implant Solutions, LLC $80 1 payment
  5. Maxx Orthopedics, Inc. $77 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,217 10 payments
  2. Travel and Lodging $321 1 payment
Products named General payments · program years 2019–2024
  1. NOVATION HIP $458 2 payments
  2. LINVATEC SHOULDER ARTHROSCOPY $382 2 payments
  3. LINVATEC EXTREMITIES $298 1 payment
  4. LINVATEC HIP PRESERVATION SYSTEM $298 1 payment
  5. LINVATEC KNEE PRESERVATION SYSTEM $298 1 payment
  6. LIVATEC KNEE PRESERVATION SYSTEM $178 2 payments
  7. OPTETRAK $116 1 payment
  8. KNEE BIOLOGICS $84 1 payment
  9. TRULIANT $60 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

178

Median for Orthopedic Surgery: 203

Drug cost

$3,026

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 71 $1,671
Oxycodone Hcl Generic 18 $281
Methylprednisolone Generic 15 $266
Cephalexin Generic 22 $255
Meloxicam Generic 22 $212
Celecoxib Generic 11 $188
Tramadol Hcl Generic 19 $154

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 124 billing codes

Paid by Medicare

$129,383

Of which drugs: $11,758

Medicare patients

465

Average age 74

Services billed

6,942

283 women, 182 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 68%
Diabetes 28%
Cancer 14%
Chronic kidney disease 13%
Osteoporosis 13%
Ischemic heart disease 9%
Atrial fibrillation 8%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 14 41 $3,970
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 122 1,126 $698
Injection, methylprednisolone acetate, 1 mg J1010 Office 53 3,099 $290

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in U.S. Virgin Islands

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record